CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, published by BEGELL HOUSE INC, serves as a vital resource within the fields of Genetics and Molecular Biology. With the ISSN 1045-4403 and E-ISSN 2162-6502, this journal has been contributing to scientific discourse since 1990 and is projected to continue its publication until 2024. Despite its classification in the Q3 quartile for both Genetics and Molecular Biology, its impact on the research community is significant, as evidenced by its diverse range of critical reviews that synthesize and analyze emerging trends and foundational studies in gene expression. The journal, located in the United States at 50 North St, Danbury, CT 06810, offers a platform for researchers, professionals, and students to engage with innovative ideas and methodologies that drive forward the understanding of gene regulatory mechanisms in eukaryotes. Although it currently does not offer open access, the journal's content remains crucial for those dedicated to advancing knowledge in the intricacies of genetic expression.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

NAR Cancer, published by Oxford University Press, is a pioneering open access journal established to advance the rapidly evolving field of cancer research. Since its inception in 2019, this journal has gained substantial recognition, achieving a prestigious Q1 ranking in both Cancer Research and Oncology categories as of 2023. With a focused objective to disseminate high-quality research, reviews, and insights into innovative cancer treatments and diagnostics, NAR Cancer serves as an essential platform for researchers, healthcare professionals, and students alike. The journal is accessible for all since it became open access in 2020, ensuring a global reach and impact. Positioned in the competitive landscape of oncology, with impressive Scopus rankings, it offers a unique opportunity for contributors to share their work with an engaged and interdisciplinary audience. With a commitment to excellence, NAR Cancer is dedicated to driving forward the understanding and management of cancer worldwide.

Epigenetics Insights is an esteemed open-access journal published by SAGE Publications Ltd since 2018, dedicated to advancing the field of epigenetics and its implications in biochemistry and genetics. With an ISSN of 2516-8657, this journal has quickly established itself as a significant player in the academic landscape, positioned in the Q3 category for both Biochemistry and Genetics based on the 2023 rankings. Our mission is to provide a forum for high-quality research that delves into the complexities of epigenetic mechanisms, their biological significance, and their potential applications in medicine and biotechnology. By embracing the principles of open access, we ensure that cutting-edge findings are readily available to researchers, professionals, and students worldwide, thereby fostering knowledge sharing and collaborative advancements in this dynamic field. With articles indexed in Scopus and a growing citation impact, Epigenetics Insights aims to engage a diverse audience and inspire innovative research practices within the global scientific community.

Epigenetics & Chromatin, published by BMC, is a leading open-access journal that has been at the forefront of research in the fields of genetics and molecular biology since its inception in 2008. With an impressive Q1 category ranking in both Genetics and Molecular Biology as of 2023, this journal is pivotal for researchers and professionals aiming to explore the complexities of gene regulation and chromatin dynamics. The journal is renowned for its commitment to disseminating high-quality research, featuring diverse articles ranging from original research to comprehensive reviews. It enjoys a significant impact within the academic community, evidenced by its Scopus rankings that place it among the top 30% of journals in Genetics and the top 40% in Molecular Biology. With a dedicated open-access model, Epigenetics & Chromatin ensures that its comprehensive content is readily accessible to researchers globally, fostering collaboration and innovation across the scientific landscape. Located in the UK, the journal continues to attract a diverse audience of scholars and practitioners passionate about understanding the intricate layers of epigenetic regulation.

Global Medical Genetics is a premier open-access journal dedicated to advancing the field of medical genetics. Published by GEORG THIEME VERLAG KG, this journal has been providing a dynamic platform for disseminating cutting-edge research and clinical findings since its inception in 2020. With the ISSN 2699-9404, it serves as an essential resource for researchers, healthcare professionals, and students who seek to explore the complex interplay between genetics and medicine. The journal aims to foster collaboration and innovation in the genetics community, addressing a diverse range of topics from genetic disorders to the application of genomics in personalized medicine. By providing open access to its content, Global Medical Genetics enhances knowledge sharing and accelerates advancements in healthcare, making it a vital asset for anyone invested in the future of genetics.

CURRENT GENOMICS is a premier journal published by Bentham Science Publishers that focuses on the expansive field of genomics, including both clinical and molecular genetics. With the ISSN 1389-2029 and E-ISSN 1875-5488, this esteemed journal has been disseminating significant scientific insights since its inception in 2000 and continues to contribute to the field through 2024. Based in the United Arab Emirates, CURRENT GENOMICS boasts a Q3 ranking in both the genetics and clinical genetics categories for 2023, reflecting its growing impact in the scientific community. Although not an open-access journal, it provides valuable content that supports researchers and professionals in navigating the complexities of genetic research and its applications. By publishing original research articles, reviews, and case studies, CURRENT GENOMICS aims to foster a deeper understanding of genomic science and its implications for medicine, thus playing a critical role in the advancement of genetics and biomedical research.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

Epigenomes is a distinguished open access journal published by MDPI, dedicated to advancing the field of epigenetics and its interdisciplinary connections to biochemistry, genetics, and molecular biology. Since its inception in 2017, this journal has provided a transparent platform for researchers to share their findings, contributing to a deeper understanding of epigenetic mechanisms and their implications in health, toxicology, and mutagenesis. Ranked in the Q2 quartile across multiple categories, including biochemistry and genetics, Epigenomes is recognized for its scholarly contributions, reflected in its notable Scopus rankings. Readers benefit from a wealth of open access articles, fostering innovation and collaboration within the academic community. With its headquarters in Switzerland and an unwavering commitment to scientific rigor, Epigenomes is positioned as a vital resource for researchers, professionals, and students seeking to deepen their insights into the epigenomic landscape.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.